Covered recipient · General Payments record
SARA SHELBY FRIEDMAN
Allopathic & Osteopathic Physicians Obstetrics & Gynecology
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
Saved only in this browser. No account or alerts.
General Payments · PY2024 · Entire year
$3,024.97
16 records · 0 disputed
“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”
— Centers for Medicare & Medicaid Services, Open Payments
A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.
These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
How these totals are calculated
- This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Methodology & Data — sourcing, labeling, and limitations.
Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗
By nature of payment
PY2024 · entire year · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Travel and Lodging | $2,418.97 | 6 |
| Food and Beverage | $606.00 | 10 |
By paying entity
PY2024 · entire year · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| ModernaTX, Inc. | $3,024.97 | 16 |
Page 1 of 1; records 1–16 of 16 matching records. This page contains 16 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.
IndustryPayments · General Payments
SARA SHELBY FRIEDMAN
NPI 1649318569 · CMS profile ID 979795
Allopathic & Osteopathic Physicians / Obstetrics & Gynecology
ALBUQUERQUE, NM
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types
Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00
Page 1 of 1; records 1–16 of 16 matching records. This page contains 16 records (maximum 50), not the full filtered export.
Filtered page: https://industrypayments.org/provider/npi-1649318569?year=2024&recipient=provider#records-h
CMS source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff
Cite these filtered records
The citation includes this program year, filters, data edition, and page of results.
- Plain
- SARA SHELBY FRIEDMAN, NPI 1649318569, CMS profile ID 979795. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–16 of 16 matching records. This page contains 16 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1649318569?year=2024&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
- APA 7
- IndustryPayments. (2026). SARA SHELBY FRIEDMAN, NPI 1649318569, CMS profile ID 979795. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–16 of 16 matching records. This page contains 16 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1649318569?year=2024&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
- Bluebook
- SARA SHELBY FRIEDMAN, NPI 1649318569, CMS profile ID 979795, IndustryPayments, General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–16 of 16 matching records. This page contains 16 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff. https://industrypayments.org/provider/npi-1649318569?year=2024&recipient=provider#records-h.
Centers for Medicare & Medicaid Services, Open Payments
Citation formats are provided for reference; check the requirements of your publication.
Payment records · PY2024
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
General Payments · PY2024 · Physicians and non-physician practitioners · CMS publication 2026-06-30
16 matching records · $3,024.97 reported total · 0 disputed
Nature of payment: All payment types
Records imported here (UTC).
CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.
Showing records 1–16 of 16.
| Paying entity | Amount | Date | Nature of payment | Dispute status | Publication flags | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|---|
| ModernaTX, Inc. | $240.00 | 09/14/2024 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1152560398 | CMS |
| ModernaTX, Inc. | $718.46 | 09/14/2024 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1152560400 | CMS |
| ModernaTX, Inc. | $531.06 | 09/14/2024 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1152560402 | CMS |
| ModernaTX, Inc. | $45.00 | 09/14/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1152560404 | CMS |
| ModernaTX, Inc. | $30.00 | 09/14/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1152560406 | CMS |
| ModernaTX, Inc. | $81.00 | 09/14/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1152560408 | CMS |
| ModernaTX, Inc. | $30.00 | 09/14/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1152560410 | CMS |
| ModernaTX, Inc. | $120.00 | 09/14/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1152560416 | CMS |
| ModernaTX, Inc. | $520.80 | 01/04/2024 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1152560382 | CMS |
| ModernaTX, Inc. | $191.30 | 01/04/2024 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1152560384 | CMS |
| ModernaTX, Inc. | $150.00 | 01/04/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1152560386 | CMS |
| ModernaTX, Inc. | $217.35 | 01/04/2024 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1152560388 | CMS |
| ModernaTX, Inc. | $50.00 | 01/04/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1152560390 | CMS |
| ModernaTX, Inc. | $25.00 | 01/04/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1152560392 | CMS |
| ModernaTX, Inc. | $50.00 | 01/04/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1152560394 | CMS |
| ModernaTX, Inc. | $25.00 | 01/04/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1152560396 | CMS |
By program year
All program years on this page · sorted by year
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-06-30
- Program years on this page
- 2019, 2023, 2024
Source files and profile matching
- Source files
- Dataset page · Bulk file · PY2019 , PY2023 , PY2024
- Generated from
- OP_DTL_GNRL_PGYR2024_P06302026_06032026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.
Research Payments
One row per program year and role, newest year first · amounts for the two roles are never added together
| Program year | Role | Amount | Records |
|---|---|---|---|
| PY2025 | Principal investigator | $1,296,266.41 | 159 |
| PY2024 | Principal investigator | $1,078,411.75 | 127 |
| PY2023 | Principal investigator | $776,040.20 | 596 |
| PY2022 | Principal investigator | $318,257.95 | 46 |
Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.
“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”
— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224
Research Payments records · PY2024
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
127 records in PY2024
| Role | Paying entity | Amount | Date | Recipient | Study | Dispute status | Published | Record ID |
|---|---|---|---|---|---|---|---|---|
| Principal investigator 1 | Merck Sharp & Dohme LLC | $53,798.18 | 12/31/2024 | Non-covered Recipient Entity Velocity Clinical Research, Albuquerque | A Phase 3, Randomized, Double-Blind Study to Evaluate the Safety, Tolerability, and Immunogenicity of V116 in Children and Adolescents With Increased Risk of Pneumococcal Disease | No dispute reported | 06/30/2026 | 1136434467 |
| Principal investigator 1 | ModernaTX, Inc. | $19,181.45 | 12/23/2024 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A PHASE 3, RANDOMIZED, OBSERVER-BLINDED, PLACEBO-CONTROLLED STUDY TO EVALUATE THE SAFETY AND EFFICACY OF MRNA-1403, A MULTIVALENT CANDIDATE VACCINE TO PREVENT NOROVIRUS ACUTE GASTROENTERITIS IN ADULTS 18 YEARS OF AGE | No dispute reported | 06/30/2026 | 1147142962 |
| Principal investigator 1 | ModernaTX, Inc. | $31,541.90 | 12/20/2024 | Non-covered Recipient Entity Velocity Clinical Research - Albuquerque - PPDS | A Phase 4, Randomized, Observer-blind, Placebo-controlled, Crossover Study to Assess Cardiac Troponin Levels after mRNA-1273.712 Vaccine in Participants 12 through 30 years of Age | No dispute reported | 06/30/2026 | 1147177406 |
| Principal investigator 1 | Currax Pharmaceuticals LLC | $1,100.00 | 12/19/2024 | Non-covered Recipient Entity Velocity Clinical Research Inc | NB (Contrave) Cardiovascular Outcomes Trial | No dispute reported | 06/30/2026 | 1089521437 |
| Principal investigator 1 | ModernaTX, Inc. | $877.50 | 12/18/2024 | Non-covered Recipient Entity Velocity Clinical Research - Albuquerque - PPDS | A Phase 3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age | No dispute reported | 06/30/2026 | 1147177396 |
| Principal investigator 1 | Vertex Pharmaceuticals Incorporated | $2,600.00 | 12/18/2024 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH ALBUQUERQUE | A Phase 3, Open-label Study Evaluating the Long-term Safety and Effectiveness of Suzetrigine in Subjects With Pain Associated With Diabetic Peripheral Neuropathy | No dispute reported | 06/30/2026 | 1155491075 |
| Principal investigator 1 | ModernaTX, Inc. | $1,247.50 | 12/13/2024 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 | No dispute reported | 06/30/2026 | 1147142834 |
| Principal investigator 1 | ModernaTX, Inc. | $790.40 | 12/13/2024 | Non-covered Recipient Entity Velocity Clinical Research - Albuquerque - PPDS | A Phase 3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age | No dispute reported | 06/30/2026 | 1147177394 |
| Principal investigator 1 | ModernaTX, Inc. | $249.45 | 12/13/2024 | Non-covered Recipient Entity Velocity Clinical Research - Albuquerque - PPDS | A PHASE 3, RANDOMIZED, OBSERVER-BLINDED, PLACEBO-CONTROLLED STUDY TO EVALUATE THE SAFETY AND EFFICACY OF MRNA-1403, A MULTIVALENT CANDIDATE VACCINE TO PREVENT NOROVIRUS ACUTE GASTROENTERITIS IN ADULTS 18 YEARS OF AGE | No dispute reported | 06/30/2026 | 1147177408 |
| Principal investigator 1 | ModernaTX, Inc. | $300.00 | 12/06/2024 | Non-covered Recipient Entity Velocity Clinical Research - Albuquerque - PPDS | A Phase 3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age | No dispute reported | 06/30/2026 | 1147177398 |
| Principal investigator 1 | ModernaTX, Inc. | $2,176.07 | 12/04/2024 | Non-covered Recipient Entity Velocity Clinical Research - Albuquerque - PPDS | A Phase 3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age | No dispute reported | 06/30/2026 | 1147177392 |
| Principal investigator 1 | ModernaTX, Inc. | $12,940.38 | 11/28/2024 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 | No dispute reported | 06/30/2026 | 1147142598 |
| Principal investigator 1 | ModernaTX, Inc. | $19,398.05 | 11/27/2024 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A PHASE 3, RANDOMIZED, OBSERVER-BLINDED, PLACEBO-CONTROLLED STUDY TO EVALUATE THE SAFETY AND EFFICACY OF MRNA-1403, A MULTIVALENT CANDIDATE VACCINE TO PREVENT NOROVIRUS ACUTE GASTROENTERITIS IN ADULTS 18 YEARS OF AGE | No dispute reported | 06/30/2026 | 1147142672 |
| Principal investigator 1 | ModernaTX, Inc. | $307.45 | 11/22/2024 | Non-covered Recipient Entity Velocity Clinical Research - Albuquerque - PPDS | A Phase 3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age | No dispute reported | 06/30/2026 | 1147177362 |
| Principal investigator 1 | ModernaTX, Inc. | $500.00 | 11/22/2024 | Non-covered Recipient Entity Velocity Clinical Research - Albuquerque - PPDS | A Phase 3, randomized, observerblind, activecontrol study to evaluate the safety, reactogenicity, and immunogenicity of mRNA1083 (SARSCoV2 and influenza) vaccine in healthy adult participants, 50 years of age. | No dispute reported | 06/30/2026 | 1147177366 |
| Principal investigator 1 | ModernaTX, Inc. | $325.00 | 11/22/2024 | Non-covered Recipient Entity Velocity Clinical Research - Albuquerque - PPDS | A Phase 3, randomized, observerblind, activecontrol study to evaluate the safety, reactogenicity, and immunogenicity of mRNA1083 (SARSCoV2 and influenza) vaccine in healthy adult participants, 50 years of age. | No dispute reported | 06/30/2026 | 1147177368 |
| Principal investigator 1 | ModernaTX, Inc. | $2,000.00 | 11/22/2024 | Non-covered Recipient Entity Velocity Clinical Research - Albuquerque - PPDS | A Phase 3, randomized, observerblind, activecontrol study to evaluate the safety, reactogenicity, and immunogenicity of mRNA1083 (SARSCoV2 and influenza) vaccine in healthy adult participants, 50 years of age. | No dispute reported | 06/30/2026 | 1147177370 |
| Principal investigator 1 | ModernaTX, Inc. | $3,300.00 | 11/22/2024 | Non-covered Recipient Entity Velocity Clinical Research - Albuquerque - PPDS | A Phase 3, randomized, observerblind, activecontrol study to evaluate the safety, reactogenicity, and immunogenicity of mRNA1083 (SARSCoV2 and influenza) vaccine in healthy adult participants, 50 years of age. | No dispute reported | 06/30/2026 | 1147177372 |
| Principal investigator 1 | ModernaTX, Inc. | $597.25 | 11/22/2024 | Non-covered Recipient Entity Velocity Clinical Research - Albuquerque - PPDS | A Phase 3, randomized, observerblind, activecontrol study to evaluate the safety, reactogenicity, and immunogenicity of mRNA1083 (SARSCoV2 and influenza) vaccine in healthy adult participants, 50 years of age. | No dispute reported | 06/30/2026 | 1147177374 |
| Principal investigator 1 | ModernaTX, Inc. | $14,262.80 | 11/21/2024 | Non-covered Recipient Entity Velocity Clinical Research - Albuquerque - PPDS | A Phase 4, Randomized, Observer-blind, Placebo-controlled, Crossover Study to Assess Cardiac Troponin Levels after mRNA-1273.712 Vaccine in Participants 12 through 30 years of Age | No dispute reported | 06/30/2026 | 1147177376 |
| Principal investigator 1 | Novo Nordisk AS | $4.50 | 11/20/2024 | Non-covered Recipient Entity VELOCITY CLIN RES ALBUQUERQUE | NN9388-7741 | No dispute reported | 06/30/2026 | 1097205921 |
| Principal investigator 1 | ModernaTX, Inc. | $68.30 | 11/19/2024 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH- NEW MEXICO | A PHASE 3, RANDOMIZED, OBSERVER-BLINDED, PLACEBO-CONTROLLED STUDY TO EVALUATE THE SAFETY AND EFFICACY OF MRNA-1403, A MULTIVALENT CANDIDATE VACCINE TO PREVENT NOROVIRUS ACUTE GASTROENTERITIS IN ADULTS 18 YEARS OF AGE | No dispute reported | 06/30/2026 | 1147152487 |
| Principal investigator 1 | Currax Pharmaceuticals LLC | $2,728.41 | 11/14/2024 | Non-covered Recipient Entity Velocity Clinical Research Inc | NB (Contrave) Cardiovascular Outcomes Trial | No dispute reported | 06/30/2026 | 1089521042 |
| Principal investigator 1 | ModernaTX, Inc. | $3,753.10 | 11/13/2024 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 | No dispute reported | 06/30/2026 | 1147142554 |
| Principal investigator 1 | VERTEX PHARMACEUTICALS INCORPORATED | $4,639.59 | 11/13/2024 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH ALBUQUERQUE | A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-design Study of the Efficacy and Safety of Suzetrigine in Subjects With Painful Diabetic Peripheral Neuropathy | No dispute reported | 06/30/2026 | 1095480810 |
| Principal investigator 1 | ModernaTX, Inc. | $7,000.00 | 11/08/2024 | Non-covered Recipient Entity Velocity Clinical Research - Albuquerque - PPDS | A Phase 4, Randomized, Observer-blind, Placebo-controlled, Crossover Study to Assess Cardiac Troponin Levels after mRNA-1273.712 Vaccine in Participants 12 through 30 years of Age | No dispute reported | 06/30/2026 | 1147177378 |
| Principal investigator 1 | Currax Pharmaceuticals LLC | $247.00 | 11/07/2024 | Non-covered Recipient Entity Velocity Clinical Research Inc | NB (Contrave) Cardiovascular Outcomes Trial | No dispute reported | 06/30/2026 | 1089519809 |
| Principal investigator 1 | ModernaTX, Inc. | $3,470.00 | 11/04/2024 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 2, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, in Children 2 to <18 Years of Age at High Risk of Respiratory Syncytial Virus Disease | No dispute reported | 06/30/2026 | 1147142606 |
| Principal investigator 1 | ModernaTX, Inc. | $102.45 | 10/31/2024 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH- NEW MEXICO | A PHASE 3, RANDOMIZED, OBSERVER-BLINDED, PLACEBO-CONTROLLED STUDY TO EVALUATE THE SAFETY AND EFFICACY OF MRNA-1403, A MULTIVALENT CANDIDATE VACCINE TO PREVENT NOROVIRUS ACUTE GASTROENTERITIS IN ADULTS 18 YEARS OF AGE | No dispute reported | 06/30/2026 | 1147152485 |
| Principal investigator 1 | Novo Nordisk AS | $53.70 | 10/31/2024 | Non-covered Recipient Entity VELOCITY CLIN RES ALBUQUERQUE | NN9388-7741 | No dispute reported | 06/30/2026 | 1097205369 |
| Principal investigator 1 | ModernaTX, Inc. | $3,698.24 | 10/25/2024 | Non-covered Recipient Entity ClinEdge, LLC - PPDS | A Phase 3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age | No dispute reported | 06/30/2026 | 1147135395 |
| Principal investigator 1 | Currax Pharmaceuticals LLC | $5,400.00 | 10/24/2024 | Non-covered Recipient Entity Velocity Clinical Research Inc | NB (Contrave) Cardiovascular Outcomes Trial | No dispute reported | 06/30/2026 | 1089519652 |
| Principal investigator 1 | Currax Pharmaceuticals LLC | $3,300.00 | 10/24/2024 | Non-covered Recipient Entity Velocity Clinical Research Inc | NB (Contrave) Cardiovascular Outcomes Trial | No dispute reported | 06/30/2026 | 1089520810 |
| Principal investigator 1 | SANOFI PASTEUR INC. | $1,536.97 | 10/23/2024 | Non-covered Recipient Entity Velocity Clinical Research,inc | A Phase I/II, Randomized, Descriptive, Safety and Immunogenicity Study to Assess Pentavalent Meningococcal ABCYW Vaccine Formulations in Adults (18 to 25 Years of Age) and Adolescents (10 to 17 Years of Age). | No dispute reported | 06/30/2026 | 1128703446 |
| Principal investigator 1 | ModernaTX, Inc. | $9,932.86 | 10/18/2024 | Non-covered Recipient Entity ClinEdge, LLC - PPDS | An Open-Label, Phase 3 Study to Evaluate the Safety and Immunogenicity of the mRNA1273.214 Vaccine for SARS-CoV-2 Variants of Concern in Participants Aged 6 Months to < 6 Years | No dispute reported | 06/30/2026 | 1147135435 |
| Principal investigator 1 | ModernaTX, Inc. | $2,976.35 | 10/18/2024 | Non-covered Recipient Entity ClinEdge, LLC - PPDS | An Open-Label, Phase 3 Study to Evaluate the Safety and Immunogenicity of the mRNA1273.214 Vaccine for SARS-CoV-2 Variants of Concern in Participants Aged 6 Months to < 6 Years | No dispute reported | 06/30/2026 | 1147135437 |
| Principal investigator 1 | Vertex Pharmaceuticals Incorporated | $18,256.05 | 10/18/2024 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH ALBUQUERQUE | A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-design Study of the Efficacy and Safety of Suzetrigine in Subjects With Painful Diabetic Peripheral Neuropathy | No dispute reported | 06/30/2026 | 1155491076 |
| Principal investigator 1 | ModernaTX, Inc. | $6,800.00 | 10/14/2024 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A PHASE 3, RANDOMIZED, OBSERVER-BLINDED, PLACEBO-CONTROLLED STUDY TO EVALUATE THE SAFETY AND EFFICACY OF MRNA-1403, A MULTIVALENT CANDIDATE VACCINE TO PREVENT NOROVIRUS ACUTE GASTROENTERITIS IN ADULTS 18 YEARS OF AGE | No dispute reported | 06/30/2026 | 1147142340 |
| Principal investigator 1 | ModernaTX, Inc. | $5,550.00 | 10/11/2024 | Non-covered Recipient Entity ClinEdge, LLC - PPDS | Phase 1/2a randomized, observer-blind, placebo-controlled, dose-ranging study of safety and immunogenicity of mRNA-1647 cytomegalovirus (CMV) vaccine in participants 9 to 15 years of age and open-label study of safety and immunogenicity of mRNA-1647 CMV vaccine in participants 9 to 25 years of age | No dispute reported | 06/30/2026 | 1147135345 |
| Principal investigator 1 | ModernaTX, Inc. | $2,000.00 | 10/11/2024 | Non-covered Recipient Entity ClinEdge, LLC - PPDS | Phase 1/2a randomized, observer-blind, placebo-controlled, dose-ranging study of safety and immunogenicity of mRNA-1647 cytomegalovirus (CMV) vaccine in participants 9 to 15 years of age and open-label study of safety and immunogenicity of mRNA-1647 CMV vaccine in participants 9 to 25 years of age | No dispute reported | 06/30/2026 | 1147135347 |
| Principal investigator 1 | ModernaTX, Inc. | $850.00 | 10/11/2024 | Non-covered Recipient Entity ClinEdge, LLC - PPDS | Phase 1/2a randomized, observer-blind, placebo-controlled, dose-ranging study of safety and immunogenicity of mRNA-1647 cytomegalovirus (CMV) vaccine in participants 9 to 15 years of age and open-label study of safety and immunogenicity of mRNA-1647 CMV vaccine in participants 9 to 25 years of age | No dispute reported | 06/30/2026 | 1147135349 |
| Principal investigator 1 | ModernaTX, Inc. | $10,171.45 | 10/02/2024 | Non-covered Recipient Entity ClinEdge, LLC - PPDS | Phase 1/2a randomized, observer-blind, placebo-controlled, dose-ranging study of safety and immunogenicity of mRNA-1647 cytomegalovirus (CMV) vaccine in participants 9 to 15 years of age and open-label study of safety and immunogenicity of mRNA-1647 CMV vaccine in participants 9 to 25 years of age | No dispute reported | 06/30/2026 | 1147135341 |
| Principal investigator 1 | ModernaTX, Inc. | $8,260.00 | 10/02/2024 | Non-covered Recipient Entity ClinEdge, LLC - PPDS | Phase 1/2a randomized, observer-blind, placebo-controlled, dose-ranging study of safety and immunogenicity of mRNA-1647 cytomegalovirus (CMV) vaccine in participants 9 to 15 years of age and open-label study of safety and immunogenicity of mRNA-1647 CMV vaccine in participants 9 to 25 years of age | No dispute reported | 06/30/2026 | 1147135343 |
| Principal investigator 1 | ModernaTX, Inc. | $7,526.00 | 10/02/2024 | Non-covered Recipient Entity ClinEdge, LLC - PPDS | Phase 1/2a randomized, observer-blind, placebo-controlled, dose-ranging study of safety and immunogenicity of mRNA-1647 cytomegalovirus (CMV) vaccine in participants 9 to 15 years of age and open-label study of safety and immunogenicity of mRNA-1647 CMV vaccine in participants 9 to 25 years of age | No dispute reported | 06/30/2026 | 1147135351 |
| Principal investigator 1 | Merck Sharp & Dohme LLC | $296.94 | 09/30/2024 | Non-covered Recipient Entity Velocity Clinical Research, Albuquerque | A Phase 3, Randomized, Double-Blind Study to Evaluate the Safety, Tolerability, and Immunogenicity of V116 in Children and Adolescents With Increased Risk of Pneumococcal Disease | No dispute reported | 06/30/2026 | 1136436578 |
| Principal investigator 1 | ModernaTX, Inc. | $5,000.00 | 09/27/2024 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A PHASE 3, RANDOMIZED, OBSERVER-BLINDED, PLACEBO-CONTROLLED STUDY TO EVALUATE THE SAFETY AND EFFICACY OF MRNA-1403, A MULTIVALENT CANDIDATE VACCINE TO PREVENT NOROVIRUS ACUTE GASTROENTERITIS IN ADULTS 18 YEARS OF AGE | No dispute reported | 06/30/2026 | 1147142092 |
| Principal investigator 1 | Currax Pharmaceuticals LLC | $1,100.00 | 09/26/2024 | Non-covered Recipient Entity Velocity Clinical Research Inc | NB (Contrave) Cardiovascular Outcomes Trial | No dispute reported | 06/30/2026 | 1089520559 |
| Principal investigator 1 | Currax Pharmaceuticals LLC | $653.26 | 09/26/2024 | Non-covered Recipient Entity Velocity Clinical Research Inc | NB (Contrave) Cardiovascular Outcomes Trial | No dispute reported | 06/30/2026 | 1089520650 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $17,450.00 | 09/25/2024 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH | A Phase IIb Randomized Double blind Placebo controlled and Open label Active Comparator Study to Evaluate the Efficacy Safety and Tolerability of AZD5004 in Adults with Type 2 Diabetes Mellitus | No dispute reported | 06/30/2026 | 1110840076 |
| Principal investigator 1 | ModernaTX, Inc. | $890.00 | 09/25/2024 | Non-covered Recipient Entity ClinEdge, LLC - PPDS | A Phase 3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age | No dispute reported | 06/30/2026 | 1147135091 |
| Principal investigator 1 | ModernaTX, Inc. | $1,000.00 | 09/25/2024 | Non-covered Recipient Entity ClinEdge, LLC - PPDS | A Phase 3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age | No dispute reported | 06/30/2026 | 1147135093 |
| Principal investigator 1 | ModernaTX, Inc. | $500.00 | 09/25/2024 | Non-covered Recipient Entity ClinEdge, LLC - PPDS | A Phase 3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age | No dispute reported | 06/30/2026 | 1147135095 |
| Principal investigator 1 | ModernaTX, Inc. | $44,935.03 | 09/25/2024 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 | No dispute reported | 06/30/2026 | 1147142008 |
| Principal investigator 1 | ModernaTX, Inc. | $2,900.00 | 09/23/2024 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 | No dispute reported | 06/30/2026 | 1147141958 |
| Principal investigator 1 | Novo Nordisk AS | $3.00 | 09/19/2024 | Non-covered Recipient Entity VELOCITY CLIN RES ALBUQUERQUE | NN9388-7741 | No dispute reported | 06/30/2026 | 1097184710 |
| Principal investigator 1 | Novo Nordisk AS | $17.90 | 09/19/2024 | Non-covered Recipient Entity VELOCITY CLIN RES ALBUQUERQUE | NN9388-7741 | No dispute reported | 06/30/2026 | 1097191777 |
| Principal investigator 1 | ModernaTX, Inc. | $2,781.22 | 09/18/2024 | Non-covered Recipient Entity ClinEdge, LLC - PPDS | A Phase 3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age | No dispute reported | 06/30/2026 | 1147135089 |
| Principal investigator 1 | ModernaTX, Inc. | $9,152.60 | 09/18/2024 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 2, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, in Children 2 to <18 Years of Age at High Risk of Respiratory Syncytial Virus Disease | No dispute reported | 06/30/2026 | 1147142032 |
| Principal investigator 1 | ModernaTX, Inc. | $399.12 | 09/13/2024 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH- NEW MEXICO | A PHASE 3, RANDOMIZED, OBSERVER-BLINDED, PLACEBO-CONTROLLED STUDY TO EVALUATE THE SAFETY AND EFFICACY OF MRNA-1403, A MULTIVALENT CANDIDATE VACCINE TO PREVENT NOROVIRUS ACUTE GASTROENTERITIS IN ADULTS 18 YEARS OF AGE | No dispute reported | 06/30/2026 | 1147152483 |
| Principal investigator 1 | Currax Pharmaceuticals LLC | $325.00 | 09/05/2024 | Non-covered Recipient Entity Velocity Clinical Research Inc | NB (Contrave) Cardiovascular Outcomes Trial | No dispute reported | 06/30/2026 | 1089519565 |
| Principal investigator 1 | ModernaTX, Inc. | $2,927.60 | 09/03/2024 | Non-covered Recipient Entity ClinEdge, LLC - PPDS | A Phase 3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age | No dispute reported | 06/30/2026 | 1147135087 |
| Principal investigator 1 | ModernaTX, Inc. | $157,464.77 | 09/02/2024 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 | No dispute reported | 06/30/2026 | 1147141892 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $17,234.00 | 08/23/2024 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH | a phase 3,global,randomized,modified double blind,placebo controlled,study to evaluate the efficacy,immunogenicity,and safety of IVX A12,a respiratory syncytial virus RSV and human metapneumovirus hMPV virus like particle VLP vaccine in adults 60 years of age and older | No dispute reported | 06/30/2026 | 1110840244 |
| Principal investigator 1 | ModernaTX, Inc. | $2,687.36 | 08/21/2024 | Non-covered Recipient Entity ClinEdge, LLC - PPDS | A Phase 3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age | No dispute reported | 06/30/2026 | 1147134769 |
| Principal investigator 1 | ModernaTX, Inc. | $21,563.84 | 08/21/2024 | Non-covered Recipient Entity ClinEdge, LLC - PPDS | An Open-Label, Phase 3 Study to Evaluate the Safety and Immunogenicity of the mRNA1273.214 Vaccine for SARS-CoV-2 Variants of Concern in Participants Aged 6 Months to < 6 Years | No dispute reported | 06/30/2026 | 1147134819 |
| Principal investigator 1 | ModernaTX, Inc. | $2,000.00 | 08/01/2024 | Non-covered Recipient Entity ClinEdge, LLC - PPDS | A Phase 3, randomized, observerblind, activecontrol study to evaluate the safety, reactogenicity, and immunogenicity of mRNA1083 (SARSCoV2 and influenza) vaccine in healthy adult participants, 50 years of age. | No dispute reported | 06/30/2026 | 1147134457 |
| Principal investigator 1 | ModernaTX, Inc. | $11,347.65 | 08/01/2024 | Non-covered Recipient Entity ClinEdge, LLC - PPDS | A Phase 3, randomized, observerblind, activecontrol study to evaluate the safety, reactogenicity, and immunogenicity of mRNA1083 (SARSCoV2 and influenza) vaccine in healthy adult participants, 50 years of age. | No dispute reported | 06/30/2026 | 1147134459 |
| Principal investigator 1 | ModernaTX, Inc. | $32,172.96 | 08/01/2024 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 | No dispute reported | 06/30/2026 | 1147141680 |
| Principal investigator 1 | ModernaTX, Inc. | $22.70 | 07/30/2024 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH- NEW MEXICO | A Phase 2, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, in Children 2 to <18 Years of Age at High Risk of Respiratory Syncytial Virus Disease | No dispute reported | 06/30/2026 | 1147152469 |
| Principal investigator 1 | ModernaTX, Inc. | $2,076.30 | 07/29/2024 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 2, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, in Children 2 to <18 Years of Age at High Risk of Respiratory Syncytial Virus Disease | No dispute reported | 06/30/2026 | 1147140638 |
| Principal investigator 1 | Currax Pharmaceuticals LLC | $7,700.00 | 07/18/2024 | Non-covered Recipient Entity Velocity Clinical Research Inc | NB (Contrave) Cardiovascular Outcomes Trial | No dispute reported | 06/30/2026 | 1089520284 |
| Principal investigator 1 | ModernaTX, Inc. | $1,223.88 | 07/17/2024 | Non-covered Recipient Entity ClinEdge, LLC - PPDS | A Phase 3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age | No dispute reported | 06/30/2026 | 1147134293 |
| Principal investigator 1 | ModernaTX, Inc. | $14,892.86 | 07/03/2024 | Non-covered Recipient Entity ClinEdge, LLC - PPDS | Phase 1/2a randomized, observer-blind, placebo-controlled, dose-ranging study of safety and immunogenicity of mRNA-1647 cytomegalovirus (CMV) vaccine in participants 9 to 15 years of age and open-label study of safety and immunogenicity of mRNA-1647 CMV vaccine in participants 9 to 25 years of age | No dispute reported | 06/30/2026 | 1147134229 |
| Principal investigator 1 | SANOFI PASTEUR INC. | $3,073.94 | 06/28/2024 | Non-covered Recipient Entity Velocity Clinical Research,inc | A Phase I/II, Randomized, Descriptive, Safety and Immunogenicity Study to Assess Pentavalent Meningococcal ABCYW Vaccine Formulations in Adults (18 to 25 Years of Age) and Adolescents (10 to 17 Years of Age). | No dispute reported | 06/30/2026 | 1128703248 |
| Principal investigator 1 | ModernaTX, Inc. | $3,437.10 | 06/27/2024 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 2, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, in Children 2 to <18 Years of Age at High Risk of Respiratory Syncytial Virus Disease | No dispute reported | 06/30/2026 | 1147141584 |
| Principal investigator 1 | ModernaTX, Inc. | $6,452.88 | 06/26/2024 | Non-covered Recipient Entity ClinEdge, LLC - PPDS | A Phase 3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age | No dispute reported | 06/30/2026 | 1147133957 |
| Principal investigator 1 | Currax Pharmaceuticals LLC | $13,500.00 | 06/13/2024 | Non-covered Recipient Entity Velocity Clinical Research Inc | NB (Contrave) Cardiovascular Outcomes Trial | No dispute reported | 06/30/2026 | 1089519079 |
| Principal investigator 1 | Currax Pharmaceuticals LLC | $247.00 | 06/06/2024 | Non-covered Recipient Entity Velocity Clinical Research Inc | NB (Contrave) Cardiovascular Outcomes Trial | No dispute reported | 06/30/2026 | 1089519447 |
| Principal investigator 1 | ModernaTX, Inc. | $1,300.00 | 06/06/2024 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 | No dispute reported | 06/30/2026 | 1147141562 |
| Principal investigator 1 | ModernaTX, Inc. | $100.50 | 06/04/2024 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH- NEW MEXICO | A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 | No dispute reported | 06/30/2026 | 1147152477 |
| Principal investigator 1 | ModernaTX, Inc. | $17,152.27 | 05/31/2024 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 | No dispute reported | 06/30/2026 | 1147141430 |
| Principal investigator 1 | ModernaTX, Inc. | $4,048.33 | 05/29/2024 | Non-covered Recipient Entity ClinEdge, LLC - PPDS | A Phase 3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age | No dispute reported | 06/30/2026 | 1147133575 |
| Principal investigator 1 | ModernaTX, Inc. | $2,046.60 | 05/27/2024 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 2, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, in Children 2 to <18 Years of Age at High Risk of Respiratory Syncytial Virus Disease | No dispute reported | 06/30/2026 | 1147141454 |
| Principal investigator 1 | ModernaTX, Inc. | $257.66 | 05/03/2024 | Non-covered Recipient Entity ClinEdge, LLC - PPDS | A Phase 3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age | No dispute reported | 06/30/2026 | 1147133609 |
| Principal investigator 1 | ModernaTX, Inc. | $100.00 | 05/02/2024 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 | No dispute reported | 06/30/2026 | 1147141346 |
| Principal investigator 1 | ModernaTX, Inc. | $7,474.24 | 04/24/2024 | Non-covered Recipient Entity ClinEdge, LLC - PPDS | A Phase 3, randomized, observerblind, activecontrol study to evaluate the safety, reactogenicity, and immunogenicity of mRNA1083 (SARSCoV2 and influenza) vaccine in healthy adult participants, 50 years of age. | No dispute reported | 06/30/2026 | 1147132887 |
| Principal investigator 1 | ModernaTX, Inc. | $4,895.54 | 04/24/2024 | Non-covered Recipient Entity ClinEdge, LLC - PPDS | A Phase 3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age | No dispute reported | 06/30/2026 | 1147133283 |
| Principal investigator 1 | SANOFI PASTEUR INC. | $1,536.97 | 04/24/2024 | Non-covered Recipient Entity Velocity Clinical Research,inc | A Phase I/II, Randomized, Descriptive, Safety and Immunogenicity Study to Assess Pentavalent Meningococcal ABCYW Vaccine Formulations in Adults (18 to 25 Years of Age) and Adolescents (10 to 17 Years of Age). | No dispute reported | 06/30/2026 | 1128703080 |
| Principal investigator 1 | ModernaTX, Inc. | $135.00 | 04/19/2024 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 2, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, in Children 2 to <18 Years of Age at High Risk of Respiratory Syncytial Virus Disease | No dispute reported | 06/30/2026 | 1147141260 |
| Principal investigator 1 | ModernaTX, Inc. | $6,830.31 | 04/12/2024 | Non-covered Recipient Entity ClinEdge, LLC - PPDS | A Phase 3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age | No dispute reported | 06/30/2026 | 1147133311 |
| Principal investigator 1 | ModernaTX, Inc. | $908.69 | 04/10/2024 | Non-covered Recipient Entity ClinEdge, LLC - PPDS | A Phase 3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age | No dispute reported | 06/30/2026 | 1147133331 |
| Principal investigator 1 | ModernaTX, Inc. | $22,821.79 | 04/05/2024 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 | No dispute reported | 06/30/2026 | 1147141246 |
| Principal investigator 1 | SANOFI PASTEUR INC. | $200.00 | 04/01/2024 | Non-covered Recipient Entity Velocity Clinical Research,inc | A Phase I/II, Randomized, Descriptive, Safety and Immunogenicity Study to Assess Pentavalent Meningococcal ABCYW Vaccine Formulations in Adults (18 to 25 Years of Age) and Adolescents (10 to 17 Years of Age). | No dispute reported | 06/30/2026 | 1128703332 |
| Principal investigator 1 | ModernaTX, Inc. | $51,888.90 | 03/28/2024 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 | No dispute reported | 06/30/2026 | 1147141018 |
| Principal investigator 1 | ModernaTX, Inc. | $1,534.95 | 03/28/2024 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 2, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, in Children 2 to <18 Years of Age at High Risk of Respiratory Syncytial Virus Disease | No dispute reported | 06/30/2026 | 1147141064 |
| Principal investigator 1 | ModernaTX, Inc. | $12,568.50 | 03/27/2024 | Non-covered Recipient Entity ClinEdge, LLC - PPDS | Phase 1/2a randomized, observer-blind, placebo-controlled, dose-ranging study of safety and immunogenicity of mRNA-1647 cytomegalovirus (CMV) vaccine in participants 9 to 15 years of age and open-label study of safety and immunogenicity of mRNA-1647 CMV vaccine in participants 9 to 25 years of age | No dispute reported | 06/30/2026 | 1147132673 |
| Principal investigator 1 | ModernaTX, Inc. | $1,664.00 | 03/27/2024 | Non-covered Recipient Entity ClinEdge, LLC - PPDS | A Phase 3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age | No dispute reported | 06/30/2026 | 1147132689 |
| Principal investigator 1 | ModernaTX, Inc. | $5,448.60 | 03/21/2024 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 2, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, in Children 2 to <18 Years of Age at High Risk of Respiratory Syncytial Virus Disease | No dispute reported | 06/30/2026 | 1147141044 |
| Principal investigator 1 | ModernaTX, Inc. | $2,057.51 | 03/20/2024 | Non-covered Recipient Entity ClinEdge, LLC - PPDS | A Phase 3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age | No dispute reported | 06/30/2026 | 1147132715 |
| Principal investigator 1 | SANOFI PASTEUR INC. | $5,075.06 | 03/18/2024 | Non-covered Recipient Entity Velocity Clinical Research,inc | A Phase I/II, Randomized, Descriptive, Safety and Immunogenicity Study to Assess Pentavalent Meningococcal ABCYW Vaccine Formulations in Adults (18 to 25 Years of Age) and Adolescents (10 to 17 Years of Age). | No dispute reported | 06/30/2026 | 1128702968 |
| Principal investigator 1 | SANOFI PASTEUR INC. | $6,612.03 | 03/18/2024 | Non-covered Recipient Entity Velocity Clinical Research,inc | A Phase I/II, Randomized, Descriptive, Safety and Immunogenicity Study to Assess Pentavalent Meningococcal ABCYW Vaccine Formulations in Adults (18 to 25 Years of Age) and Adolescents (10 to 17 Years of Age). | No dispute reported | 06/30/2026 | 1128702976 |
| Principal investigator 1 | ModernaTX, Inc. | $5,273.10 | 03/15/2024 | Non-covered Recipient Entity ClinEdge, LLC - PPDS | Phase 1/2a randomized, observer-blind, placebo-controlled, dose-ranging study of safety and immunogenicity of mRNA-1647 cytomegalovirus (CMV) vaccine in participants 9 to 15 years of age and open-label study of safety and immunogenicity of mRNA-1647 CMV vaccine in participants 9 to 25 years of age | No dispute reported | 06/30/2026 | 1147132677 |
| Principal investigator 1 | ModernaTX, Inc. | $225.00 | 03/15/2024 | Non-covered Recipient Entity ClinEdge, LLC - PPDS | A Phase 3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age | No dispute reported | 06/30/2026 | 1147132699 |
| Principal investigator 1 | ModernaTX, Inc. | $923.00 | 03/15/2024 | Non-covered Recipient Entity ClinEdge, LLC - PPDS | A Phase 3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age | No dispute reported | 06/30/2026 | 1147132701 |
| Principal investigator 1 | ModernaTX, Inc. | $43,900.72 | 03/08/2024 | Non-covered Recipient Entity ClinEdge, LLC - PPDS | A Phase 3, randomized, observerblind, activecontrol study to evaluate the safety, reactogenicity, and immunogenicity of mRNA1083 (SARSCoV2 and influenza) vaccine in healthy adult participants, 50 years of age. | No dispute reported | 06/30/2026 | 1147132417 |
| Principal investigator 1 | ModernaTX, Inc. | $2,614.49 | 03/08/2024 | Non-covered Recipient Entity ClinEdge, LLC - PPDS | A Phase 3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age | No dispute reported | 06/30/2026 | 1147132745 |
| Principal investigator 1 | ModernaTX, Inc. | $28,031.40 | 02/28/2024 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 2, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, in Children 2 to <18 Years of Age at High Risk of Respiratory Syncytial Virus Disease | No dispute reported | 06/30/2026 | 1147140820 |
| Principal investigator 1 | Merck Sharp & Dohme LLC | $14,500.00 | 02/24/2024 | Non-covered Recipient Entity Velocity Clinical Research, Albuquerque | A Phase 3, Randomized, Double-Blind Study to Evaluate the Safety, Tolerability, and Immunogenicity of V116 in Children and Adolescents With Increased Risk of Pneumococcal Disease | No dispute reported | 06/30/2026 | 1136434463 |
| Principal investigator 1 | ModernaTX, Inc. | $1,608.39 | 02/22/2024 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 | No dispute reported | 06/30/2026 | 1147140790 |
| Principal investigator 1 | ModernaTX, Inc. | $150.00 | 02/21/2024 | Non-covered Recipient Entity ClinEdge, LLC - PPDS | A Phase 3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age | No dispute reported | 06/30/2026 | 1147132049 |
| Principal investigator 1 | ModernaTX, Inc. | $357.50 | 02/21/2024 | Non-covered Recipient Entity ClinEdge, LLC - PPDS | A Phase 3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age | No dispute reported | 06/30/2026 | 1147132051 |
| Principal investigator 1 | ModernaTX, Inc. | $877.50 | 02/21/2024 | Non-covered Recipient Entity ClinEdge, LLC - PPDS | A Phase 3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age | No dispute reported | 06/30/2026 | 1147132061 |
| Principal investigator 1 | ModernaTX, Inc. | $375.00 | 02/21/2024 | Non-covered Recipient Entity ClinEdge, LLC - PPDS | A Phase 3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age | No dispute reported | 06/30/2026 | 1147132063 |
| Principal investigator 1 | ModernaTX, Inc. | $2,574.18 | 02/16/2024 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 | No dispute reported | 06/30/2026 | 1147140782 |
| Principal investigator 1 | ModernaTX, Inc. | $55,991.00 | 02/14/2024 | Non-covered Recipient Entity ClinEdge, LLC - PPDS | A Phase 3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age | No dispute reported | 06/30/2026 | 1147132087 |
| Principal investigator 1 | ModernaTX, Inc. | $12,593.29 | 02/09/2024 | Non-covered Recipient Entity ClinEdge, LLC - PPDS | A Phase 3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age | No dispute reported | 06/30/2026 | 1147132067 |
| Principal investigator 1 | ModernaTX, Inc. | $84.50 | 02/07/2024 | Non-covered Recipient Entity ClinEdge, LLC - PPDS | A Phase 3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age | No dispute reported | 06/30/2026 | 1147131999 |
| Principal investigator 1 | ModernaTX, Inc. | $825.00 | 02/01/2024 | Non-covered Recipient Entity ClinEdge, LLC - PPDS | A Phase 3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age | No dispute reported | 06/30/2026 | 1147132001 |
| Principal investigator 1 | ModernaTX, Inc. | $8,000.00 | 02/01/2024 | Non-covered Recipient Entity ClinEdge, LLC - PPDS | A Phase 3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age | No dispute reported | 06/30/2026 | 1147132009 |
| Principal investigator 1 | ModernaTX, Inc. | $1,780.00 | 02/01/2024 | Non-covered Recipient Entity ClinEdge, LLC - PPDS | A Phase 3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age | No dispute reported | 06/30/2026 | 1147132011 |
| Principal investigator 1 | ModernaTX, Inc. | $500.00 | 02/01/2024 | Non-covered Recipient Entity ClinEdge, LLC - PPDS | A Phase 3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age | No dispute reported | 06/30/2026 | 1147132013 |
| Principal investigator 1 | ModernaTX, Inc. | $1,174.50 | 01/24/2024 | Non-covered Recipient Entity ClinEdge, LLC - PPDS | Phase 1/2a randomized, observer-blind, placebo-controlled, dose-ranging study of safety and immunogenicity of mRNA-1647 cytomegalovirus (CMV) vaccine in participants 9 to 15 years of age and open-label study of safety and immunogenicity of mRNA-1647 CMV vaccine in participants 9 to 25 years of age | No dispute reported | 06/30/2026 | 1147131703 |
| Principal investigator 1 | ModernaTX, Inc. | $4,334.10 | 01/17/2024 | Non-covered Recipient Entity ClinEdge, LLC - PPDS | A Phase 3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age | No dispute reported | 06/30/2026 | 1147131683 |
| Principal investigator 1 | ModernaTX, Inc. | $1,665.90 | 01/17/2024 | Non-covered Recipient Entity ClinEdge, LLC - PPDS | A Phase 3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age | No dispute reported | 06/30/2026 | 1147131685 |
| Principal investigator 1 | ModernaTX, Inc. | $63,988.47 | 01/16/2024 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 | No dispute reported | 06/30/2026 | 1147140476 |
| Principal investigator 1 | PFIZER INC. | $4,460.00 | 01/10/2024 | Non-covered Recipient Entity Velocity Clinical Research Inc | A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCINE AGAINST INFLUENZA COMPARED TO LICENSED INACTIVATED INFLUENZA VACCINE IN HEALTHY ADULTS 18 YEARS OF AGE OR OLDER | No dispute reported | 06/30/2026 | 1131106512 |
| Principal investigator 1 | PFIZER INC. | $1,700.00 | 01/03/2024 | Non-covered Recipient Entity Velocity Clinical Research Inc | A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCINE AGAINST INFLUENZA COMPARED TO LICENSED INACTIVATED INFLUENZA VACCINE IN HEALTHY ADULTS 18 YEARS OF AGE OR OLDER | No dispute reported | 06/30/2026 | 1131108495 |